Short answer
MIMEDX GROUP, INC. (MDXG) filed its Q2 2026 10-Q quarterly report on Jul 29, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $64M (down 34.7% year over year) with net income of −$15M.
Q2 2026 key financials · XBRL
- Revenue
- $64M
- −34.7% YoY · +9.1% QoQ
- Net income
- −$15M
- −254.3% YoY · −36.6% QoQ
- Operating margin
- -28.7%
- Gross margin
- 69.0%
- EPS (diluted)
- −$0.10
- −266.7% YoY · −42.9% QoQ
Source: XBRL data from the MIMEDX GROUP, INC. (MDXG) Q2 2026 10-Q on SEC EDGAR. USD.
MIMEDX GROUP, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $64.4M, down 34.7% YoY from $98.6M
- Gross margin 69.0% vs 81.1% YoY; GAAP net loss $14.8M vs $9.6M income
- Best segment Surgical revenue $39.3M, up 15.1%; worst Wound revenue $25.1M, down 61.1%
- Cash $135.8M; six-month operating cash flow $(8.1)M vs $19.7M; Q2 repurchases $12.5M
- Medicare reimbursement changes, credit deterioration, and cost-reduction severance remained near-term headwinds; liquidity expected for twelve months
Risk Factors
- No material changes from the 2025 Form 10-K risk factors
- No newly triggered risk factor disclosed in the quarter
- No regulatory, legal, compliance, operational, competitive, market, or financial risk updates provided
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MIMEDX GROUP, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.